持续性/慢性免疫性血小板减少症成人患者长期接受艾曲泊帕治疗的健康相关生活质量变化:EXTEND研究结果
EXTEND开放标签研究(2006年6月至2015年7月)评估艾曲泊帕治疗持续性/慢性免疫性血小板减少症成人的长期安全性、耐受性和疗效,并分析302例患者健康相关生活质量变化。四种经验证量表均显示较基线正向平均变化,且与血小板应答正相关;FACIT-疲劳和FACT-Th6的改善在3个月内出现并持续至治疗5年。
要点
- 艾曲泊帕治疗中位2.37年,四种生活质量量表均显示较基线正向平均变化。
- 生活质量改善与血小板应答(≥30×10^9/L、≥50×10^9/L等)呈正相关。
- FACIT-疲劳和FACT-Th6改善在3个月内出现并持续至5年(几乎所有时间点P<.05)。
核心结论
- 艾曲泊帕除增加血小板计数、减少出血/瘀伤外,还减轻疲劳和对出血/瘀伤的担忧,并改善许多患者的躯体功能,尤其在应答者中。
研究设计与样本
- 开放标签EXTEND研究(2006年6月至2015年7月)评估艾曲泊帕在完成既往艾曲泊帕ITP试验的持续性/慢性免疫性血小板减少症成人中的长期安全性、耐受性和疗效。
- 共纳入302例患者,艾曲泊帕治疗中位持续时间为2.37年。
主要发现
- 四种经验证的生活质量量表(SF-36v2含PCS和MCS、MEI-SF、FACIT-疲劳、FACT-Th6)均显示,在调整患者基线特征和挽救治疗使用后,较基线的平均变化为正向。
- 生活质量与血小板应答(血小板计数≥30×10^9/L、≥50×10^9/L、以及≥50×10^9/L且>2倍基线)呈正相关。
- FACIT-疲劳和FACT-Th6的改善从基线起3个月内开始,并持续至治疗5年(几乎所有时间点P<.05)。
- SF-36v2 PCS的改善持续至2.5年,MEI-SF的改善一致性较低。
关键数值与推荐
- 血小板应答定义:血小板计数≥30×10^9/L;≥50×10^9/L;≥50×10^9/L且>2倍基线。
- FACIT-疲劳和FACT-Th6改善持续至5年,几乎所有时间点P<.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with persistent/chronic immune thrombocytopenia (cITP) have low platelet counts, increased risk of bleeding and bruising, and often suffer from reduced health-related quality of life (HRQoL). cITP treatments may either improve HRQoL by increasing platelet counts or decrease it because of side effects. The open-label EXTEND study (June 2006 to July 2015) evaluated long-term safety, tolerability, and efficacy of eltrombopag (an oral thrombopoietin-receptor-agonist) in adults with cITP who completed a previous eltrombopag ITP trial. The final results of EXTEND were published and used to assess changes in patient-reported HRQoL over time and association between HRQoL and platelet response. Four validated HRQoL instruments were administered: SF-36v2 including physical component summary (PCS) and Mental Component Summary; Motivation and Energy Inventory Short Form (MEI-SF); Fatigue Subscale of FACIT (FACIT-Fatigue); and FACT-Thrombocytopenia Subscale Six-Item Extract (FACT-Th6). For the 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years. All 4 HRQoL instruments demonstrated positive mean changes from baseline over time adjusted for patient baseline characteristics and rescue therapy use, and had positive association with platelet response (platelet count ≥30 × 109 /L; ≥50 × 109 /L; and ≥50 × 109 /L and >2 times baseline). Improvements from baseline started within 3 months and persisted through 5 years of treatment for FACIT-Fatigue and FACT-Th6 (P <.05 for nearly all time points); through 2.5 years for SF-36v2 PCS and less consistently for the MEI-SF. In conclusion, in addition to eltrombopag increasing platelet counts and reducing bleeding/bruising, it also alleviated fatigue, concerns about bleeding and bruising, and improved physical function in many patients, especially responders.
引用
- Khelif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. Am J Hematol. 2018. PMID: 30417939. doi:10.1002/ajh.25348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。